PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Donanemab - Alzheimers disease

PAD Profile : Donanemab - Alzheimers disease Important

Brand Names Include :
Kisunla
Important Information :
Important safety information - see narrative by clicking on the drug name

Traffic Light Status

Status 1 of 1.

Status :
N/A
Formulations :
  • Intravenous infusion
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD2
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
04 December 2024
Not Set

This drug has not yet been assessed for formulary status.
If a patient is accessing non-NHS supplies of this medication, refer to the NHSE information here  (for a similar drug called lecanemab) which provides advice for clinical teams who may be asked to support referrals for private treatment or otherwise assess, advise and possibly treat a small number of patients who could present with potential adverse treatment effects, including symptomatic Amyloid-Related Imaging Abnormalities (ARIA).

This drug not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

NICE are due to publish guidance on this drug in March 2025 and this will be considered by the APC within 90 days of publication.

Associated BNF Codes

19. Other Drugs and Preparations
19.05.00. Other preparations
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More